Sign Out
Zoltax: Adults: Usual Oral Dose: Uncomplicated Urinary Tract Infections: 125 mg twice daily.
Respiratory Tract Infections: 250-500 mg twice daily.
Pneumonia or Acute Exacerbations of Chronic Bronchitis: Adults: May respond to sequential therapy with parental cefuroxime 1.5 g twice daily or 750 mg twice daily, respectively, followed by oral cefuroxime 500 mg twice daily in each case.
Lyme Disease: 500 mg oral dose twice daily for 20 days.
Uncomplicated Gonorrhea: 1 g single oral dose and probenecid 1 g may be given.
Renal Impairment: Doses may need to be reduced in patients with renal impairment.
Zoltax Injection: Adults: Usual Dose: 750 mg to 1.5 g every 8 hrs, usually for 5-10 days.
Uncomplicated Urinary Tract Infections, Skin and Skin Structure Infections, Disseminated Gonococcal Infections and Uncomplicated Pneumonia: 750 mg every 8 hrs is recommended.
Severe or Complicated Infections: 1.5 g dose every 8 hrs.
Bone and Joint Infections: 1.5 g dose every 8 hrs. In clinical trials, surgical intervention was performed when indicated as an adjunct to cefuroxime therapy. A course of oral antibiotics was administered when appropriate following the completion of parenteral administration of cefuroxime.
Life-Threatening Infections or Infections Due to Less Susceptible Organisms: 1.5 g every 6 hrs may be required.
Bacterial Meningitis: The dosage should not exceed 3 g every 8 hrs.
Preventive Use for Clean, Contaminated or Potentially Contaminated Surgical Procedure: 1.5-g dose administered IV just before surgery (approximately ½-1 hr before the initial incision) is recommended. Thereafter, give 750 mg IV every 8 hrs when the procedure is prolonged.
Preventive Use During Open Heart Surgery: 1.5-g dose administered IV at the induction of anesthesia and every 12 hrs thereafter for a total of 6 g is recommended.
Renal Impairment: A reduced dosage must be employed when renal function is impaired. Dosage should be determined by the degree of renal impairment and the susceptibility of the causative organism.
Since cefuroxime is dialyzable, patients on hemodialysis should be given a further dose at the end of the dialysis.
Note: As with antibiotic therapy in general, administration of cefuroxime for injection should be continued for a minimum of 48-72 hrs after the patient becomes asymptomatic or after evidence of bacterial eradication has been obtained; a minimum of 10 days of treatment is recommended in infections caused by Streptococcus pyogenes in order to guard against the risk of rheumatic fever or glomerulonephritis; frequent bacteriologic and clinical appraisal is necessary during therapy of chronic UTI and may be required for several months after therapy has been completed. Persistent infections may require treatment for several weeks and doses smaller than those indicated previously should not be used. In staphylococcal and other infections involving a collection of pus, surgical drainage should be carried out where indicated.
Children >3 Months: 50-100 mg/kg/day in equally divided doses every 6-8 hrs has been successful for most infections susceptible to cefuroxime. Severe Serious Infections: Higher dosage of 100 mg/kg/day (not to exceed maximum adult dose).
Bone and Joint Infections: 150 mg/kg/day (not to exceed the maximum adult dosage) is recommended in equally divided doses every 8 hrs. In clinical trials, course of oral antibiotics was administered to pediatric patients following the completion of parenteral administration of cefuroxime.
Bacterial Meningitis: A larger dosage of cefuroxime is recommended 200-240 mg/kg/day IV in divided doses every 6-8 hrs.
Children with Renal Impairment: The frequency of dosing should be modified consistent with the recommendation for adults.
Administration: The reconstituted injection is given by deep IM injection into a large muscle mass (eg, the gluteus or lateral part of the thigh). Before injecting IM, aspiration is necessary to avoid inadvertent injection in a blood vessel.
For direct intermittent IV administration, slowly inject over a period of 3-5 min or give it through the tubing system by which the patient is also receiving other IV solutions.
For intermittent IV infusion with a V-type administration set, dosing can be accomplished through the tubing system by which the patient may be receiving other IV solutions. However, during infusion of the solution containing cefuroxime, it is advisable to temporarily discontinue administration of any other solutions at the same site.
